Food, Drugs, Healthcare, Life Sciences

Singh and Kunte posited that higher consolidation might allow participating PE firms to negotiate higher reimbursements and to increase imaging utilization in the market, potentially driving profitability.

The resolution was announced following a partial intervention for the purposes of settlement by DOJ's Civil Division, in coordination with the U.S. Attorney's Office for the Central District of California and HHS-OIG

The independent pharmacy space has seen a significant uptick in transactional activity over the past few years.

Singh and Kunte posited that higher consolidation might allow participating PE firms to negotiate higher reimbursements and to increase imaging utilization in the market, potentially driving profitability.

On March 19, 2025, Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22...

The resolution was announced following a partial intervention for the purposes of settlement by DOJ's Civil Division, in coordination with the U.S. Attorney's Office for the Central District of California and HHS-OIG

In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.

After the Supreme Court decided that the personalized medicine method claims at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc. did not satisfy the patent eligibility requirements of 35 USC § 101.

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.

Singh and Kunte posited that higher consolidation might allow participating PE firms to negotiate higher reimbursements and to increase imaging utilization in the market, potentially driving profitability.

The resolution was announced following a partial intervention for the purposes of settlement by DOJ's Civil Division, in coordination with the U.S. Attorney's Office for the Central District of California and HHS-OIG

The independent pharmacy space has seen a significant uptick in transactional activity over the past few years.